Catalyst Pharmaceutical CPRX Accretion Of Discount
Accretion Of Discount at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept cprx:AccretionOfDiscount.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's accretion of discount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's accretion of discount?
- Catalyst Pharmaceutical (CPRX) reported accretion of discount of $135K in Q1 2026.
- How has Catalyst Pharmaceutical's accretion of discount changed year-over-year?
- Catalyst Pharmaceutical's accretion of discount increased by 125.0% year-over-year, from $60K to $135K.
- What is the long-term trend for Catalyst Pharmaceutical's accretion of discount?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's accretion of discount has grown at a 189.3% compound annual growth rate (CAGR), from $5K to $350K.
- What does accretion of discount mean?
- This represents the non-cash adjustment to the carrying value of financial liabilities or assets over time, typically reflecting the amortization of a discount or premium. It is used to reconcile net income to cash flow from operations by accounting for the effective interest method on debt instruments or long-term obligations. Investors monitor this to understand the non-cash impact of financing arrangements on reported earnings.